In recent years, a number of new, effective treatments have become available for advanced kidney cancer. However, with more drugs available it has become more difficult to decide which drugs to choose for particular patients, and in which order to use them. In addition, the new treatments do not work for all patients and they […]
Results from the phase 3 KEYNOTE-581/CLEAR trial show that the combination of pembrolizumab plus lenvatinib significantly improved the time taken for the cancer to start growing again (progression-free survival), overall survival, and the response rate compared with sunitinib, when used for untreated patients with advanced renal cell carcinoma (RCC). The pembrolizumab/lenvatinib combination had similar side […]
The UK has embarked on a large-scale vaccination programme to protect the population against COVID-19, with Margaret Keenan becoming the first in the world to receive the Pfizer/BioNTech COVID-19 vaccine outside of clinical trials today (8 December), in what many are describing as a landmark moment in the pandemic. Read more in PharmaTimes here
During this online interview, the approach to selection of first-line treatment for patients with metastatic renal cell carcinoma (RCC) was discussed. Traditionally, the selection of initial treatments was very straightforward, and patients were treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors, (TKIs) such as sunitinib and pazopanib. Over the past 2 years, decisions […]
A recent phase 1 trial showed that treatment with nivolumab before surgery (neoadjuvant treatment) was tolerable in patients with high-risk clear cell renal cell carcinoma (RCC) that had not spread. These results were presented at the 21st Annual Meeting of the Society of Urologic Oncology (SUO). The study was a phase 1 trial that looked […]
A recent study published at the 21st Annual Meeting of the Society of Urologic Oncology (SUO) concluded that active surveillance is a safe and long lasting management strategy for some patients with small renal masses, which are suspected to be stage T1a (≤4 cm) renal cell carcinoma (RCC). The researchers found the cancer-specific survival rate […]
As with most cancers, the psychosocial effects of renal cell carcinoma (RCC) are profound. Around 20% of patients experience depression and 30% experience anxiety due to various reasons, such as treatment side effects, disease-related changes, finances and coping strategies. Not only are these symptoms distressing, they can also affect survival. This was described using two […]
The UK has become the first country in the world to approve the Pfizer/BioNTech coronavirus vaccine, paving the way for mass vaccination. Britain’s medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), says the vaccine, which offers up to 95% protection against COVID-19, is safe to be rolled out throughout the UK. The first […]
The NHS has launched a programme to encourage patients to have any potential cancer symptoms checked out: NHS staff have worked hard to ensure that cancer services have been maintained throughout the pandemic. Between March and September, over 1 million people were referred by their GP with suspected cancer, and over 291,000 cancer treatments were […]
In this review, the key substances found in the blood, such as circulating free (cf)DNA, cfRNA, proteins, and exosomes (sacs containing proteins, DNA and/or RNA), which may act as biomarkers for monitoring the progression of clear cell renal cell carcinoma (ccRCC) are discussed. Limitations of these techniques and promising technologies that could help with the […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
